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ABSTRACT
Objective: To examine the cost-effectiveness of using
recombinant human erythropoietin (rHuEPO) to reduce
red blood cells (RBC) transfusions in intensive care unit
(ICU) patients.
Methods: Decision analysis examining costs and effec-
tiveness of using rHuEPO versus not using rHuEPO in a
simulated adult medical/surgical/trauma (mixed) ICU.
Two independent cost-effectiveness models were created
based on the results of two multicenter studies that inves-
tigated the use of rHuEPO. Base case assumptions and
estimates of effectiveness were obtained from these two
studies. Mean cumulative doses of rHuEPO were 190,900
units and 102,400 units for studies 1 and 2, respectively.
The models accounted for the deferral rate for allogeneic
RBC transfusions, rHuEPO efﬁcacy (the reduction in all-
ogeneic RBC use), and adverse effects of rHuEPO and
allogeneic RBC transfusions. Model estimates were
obtained from published sources. Costs were expressed in
2002 US dollar ($) and effectiveness was measured using
discounted quality-adjusted life-years (QALYs). A 3%
discount  rate  was  used.  Probabilistic  sensitivity  analy-
sis was conducted using second-order Monte Carlo
simulation.
Results: Incremental costs of using rHuEPO to reduce
RBC transfusions amounted to $1918 and $1439; incre-
mental effectiveness values were 0.0563 QALYs and
0.0305 QALYs; and the cost-effectiveness ratios were
$34,088 and $47,149 per QALY for studies 1 and 2,
respectively. The model was most sensitive to the attrib-
utable risk of nosocomial bacterial infections per RBC
unit. rHuEPO was cost-effective in 52.0% of the Monte
Carlo simulations for a willingness to pay of $50,000/
QALY.
Conclusion: rHuEPO appears to be cost-effective for
reducing RBC transfusions in heterogeneous ICU popu-
lations, assuming RBC transfusions increase the risk of
nosocomial bacterial infections.
Keywords: anemia, cost-effectiveness, costs, critical care,
erythropoietin, transfusion.
Introduction
Anemia occurs in approximately 75% to 95% of
patients admitted to the intensive care unit (ICU)
for at least 3 days [1–5] and is associated with
lengthened ICU stay [3–5]. The most prominent fac-
tors contributing to the development of anemia in
the ICU include preexisting renal failure, decreased
production and survival of red blood cells (RBC),
gastrointestinal blood losses, and iatrogenic blood
losses from phlebotomy [2–4]. Treatment of ICU-
associated anemia frequently involves the adminis-
tration of allogeneic RBC transfusions but the
number of transfusions is independently associated
with lengthened ICU stay and mortality. Consensus
guidelines for ICU transfusion practices recommend
restricting RBC transfusions for the purpose of
decreasing signs, symptoms, and morbidity associ-
ated with poor tissue oxygenation related to low
hematocrit (Hct) or hemoglobin (Hb) but speciﬁc
threshold values are rarely provided [6–11].
In clinical practice, RBC transfusions are pro-
vided for multiple indications. The most common
reasons are bleeding episodes, the augmentation of
oxygen delivery, surgery, and myocardial ischemia
[11–13]. Nevertheless, the administration of RBC
transfusions is an independent risk factor for hos-
pital mortality [3,4]. Liberal transfusion strategies
may further increase the mortality risk [14]. Mor-
tality may be related to transfusion-induced adverse
effects, increased infection risk [3,4,15–28], or the
administration of RBCs that have lost their cellular
deforming or oxygen carrying capacities because of
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prolonged storage [6,29,30]. The deleterious effects,
the  limited  supply  of  RBC  transfusions,  and the
costs associated with RBC transfusions have caused
transfusion practices to be reevaluated [7,31],
necessitating the exploration of alternative thera-
peutic and preventive strategies for ICU-associated
anemia.
Recombinant human erythropoietin (rHuEPO) is
a promising pharmacological approach for treating
and preventing ICU-associated anemia and reduc-
ing the number of RBC transfusions. The pro-
inﬂammatory cytokines, interleukin (IL)-1b and
tumor necrosis factor (TNF)-a, directly suppress
bone marrow production of reticulocytes [1,32] and
have restrictive effects on reticulocytosis by inhibit-
ing erythropoietin production at the nuclear level
[33,34]. In addition, interferon (IFN)-b, IFN-g, and
TNF-a blunt erythropoietin response at the level of
the receptor on RBC precursor cells [35]. Therefore,
inhibited erythropoietin production and reduced
erythropoietin response contribute to ICU-associated
anemia. The results of prospective studies have
demonstrated that early administration of rHuEPO
to critically ill patients increases reticulocyte counts
and reduces RBC transfusion requirements [36–41].
Some institutions are using rHuEPO in critically ill
patients to reduce RBC transfusion requirements
[42]. The acquisition cost of rHuEPO is very expen-
sive, however, and it is unclear whether the concom-
itant reduction in RBC transfusion requirements
offsets other possible signiﬁcant downstream costs.
A rudimentary cost analysis included in the discus-
sion of one study suggests that using rHuEPO to
prevent anemia may produce cost savings depend-
ing on the rHuEPO dosage regimen and relative
reduction in RBC transfusions [38]. To date,
comprehensive  economic  models  examining  the
cost-effectiveness  of  using  rHuEPO  in  an  ICU
population are nonexistent. The purpose of this
study was to assess the cost-effectiveness of
rHuEPO for preventing RBC transfusions in criti-
cally ill patients using the results of two previously
published clinical trials [38,39].
Methods
Decision Analysis
Decision analysis was used to model the costs and
effectiveness of utilizing rHuEPO for reducing and
possibly preventing RBC transfusions in an adult
medical/surgical/trauma (mixed) ICU from a soci-
etal perspective (Fig. 1). Two independent cost-
effectiveness models were created based on the
results of two multicenter clinical trials that inves-
tigated the  use  of  rHuEPO  for  the  prevention
of RBC transfusions (one model for each study)
[38,39]. These two studies were chosen because
they represent the largest trials enrolling mixed ICU
patients and they used methods of high quality. The
search strategy to identify these two studies has
been previously described [43]. Two models were
created because the methodologies of the two stud-
ies differ substantially. The primary decision node
of both models was whether or not to use rHuEPO.
The clinical pathway within the models depicted
patients receiving or not receiving allogeneic RBC
transfusions and the associated adverse effects of
rHuEPO and RBC transfusions. The immediate and
lifetime costs for each intervention were modeled
using estimates from the published literature. All
costs are expressed in 2002 US dollars ($) using an
annual discount rate of 3%. The analysis adhered to
Figure 1 Decision analysis of  utilizing
rHuEPO for reducing RBC transfusions.
ICU, intensive care unit; rHuEPO, recom-
binant human erythropoietin; RBC, red
blood cell; ADR, adverse drug reaction;
DVT, deep venous thrombosis; ALI, acute
lung injury; HR; hemolytic reaction; FR,
febrile reaction; UTI, urinary tract infec-
tion; HTLV, human T-cell lymphotrophic
virus; HIV, human immunodeﬁciency virus;
HB, hepatitis B; HC, hepatitis C; *Same as
RBC (No rHuEPO); †Same as Nonfatal
(ALI); ‡Same as FR (Nonfatal).
No ADR
Thrombocytopenia
DVT
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the recommendations of the Panel on Cost-
Effectiveness in Health and Medicine [44]. The
models were constructed using decision analysis
software (DATA Professional, TreeAge Software,
Inc, Williamston, MA, 2003) and Microsoft Excel
software (Microsoft Corporation, Redmond, WA,
2000). Primary output parameters of the models
were expected costs, expected effectiveness (dis-
counted quality-adjusted life-years [QALYs]), and
incremental cost-effectiveness.
Model Assumptions
For the base case analyses, the proﬁles of two mixed
ICU patient cohorts were simulated from the two
multicenter studies [38,39]. Both studies investi-
gated patients of 18 years old or above already in
the ICU for 2 or more days with an additional
expected ICU stay of 3 or more days. Study 1
enrolled 54% male with an average age of 60 years
and the majority of patients having primary diag-
noses relating to respiratory illnesses [38] whereas
study 2 enrolled 61.9% male with an average age of
51 years and the majority of patients having pri-
mary diagnoses relating to trauma or surgery [39].
The rHuEPO dosage regimens modeled were
23,000 units administered subcutaneously for 8.3
doses, daily for the ﬁrst 5 days then every other day,
and 40,000 units administered subcutaneously
every week for 2.56 doses based on studies 1 and 2,
respectively [38,39]. The doses and number of doses
are weighted means extracted from the two studies.
Both studies initiated rHuEPO when Hct fell below
38%. Iron was administered enterally at a daily
elemental dose of 150 mg as generic liquid ferrous
sulfate.
The models accounted for the following factors:
the deferral rate for allogeneic RBC transfusions,
rHuEPO efﬁcacy, the reduction in allogeneic blood
use, and adverse effects of rHuEPO and allogeneic
RBC transfusions. The only clinically relevant ben-
eﬁt of using rHuEPO demonstrated in both studies
was a reduction in transfusion requirements
[38,39]. In study 1, 55% of patients in the no
rHuEPO group required 6.93 RBC units per patient
and 45% of patients in the rHuEPO group required
4.61 RBC units per patient [38]. In study 2, 60.4%
of patients in the no rHuEPO group required 4.98
RBC units per patient and 50.5% of patients in the
rHuEPO group required 4.85 RBC units per patient
[39]. Transfusions were administered according to
clinical judgment in study 1 and to maintain an Hct
of 27% in study 2 [38,39].
The 2002 average wholesale price for rHuEPO
was discounted 15% to reﬂect the average institu-
tional contract  in  the  United  States,  resulting  in
a cost of $0.0119 per unit [45]. Including the costs
associated with administration (pharmacy and
nursing time), concurrent enteral iron administra-
tion, and a baseline erythropoietin serum con-
centration, the total cost of rHuEPO therapy was
$2561 for study 1 and $1508 for study 2 [38,39].
The cost of administering a unit of RBC included
the costs associated with blood collection (including
donor time) and storage, typing, screening, cross-
matching, nurse administration, and follow up lab-
oratory determination of Hct and was estimated at
$297. These estimates were based on published data
from different sources that were consistent between
reports [46–48]. We did not assume universal leu-
codepletion because it is unclear whether this prac-
tice alters the outcome of critically ill patients
[49,50].
The adverse effects of rHuEPO considered were
deep venous thrombosis (DVT) and thrombocyto-
penia with attributable occurrence rates of 3% [46–
48] and 7.5% [38] and associated direct costs of
$4599 [51–53] and $2896 [54], respectively.
Adverse effects of allogeneic RBC transfusions
considered were acute lung injury (ALI); hemolytic
reaction (HR); febrile reactions (FR); viral infec-
tions including human immunodeﬁciency virus
(HIV), hepatitis B (HB), hepatitis C (HC), and
human T-cell lymphotrophic virus (HTLV); and
bacterial infections including sepsis, pneumonia,
bacteremia, and urinary tract infections (Table 1)
[3,6,15,55–62]. The nosocomial bacterial infection
rates for patients not requiring RBC transfusions
(baseline infection rates) were 0.15%, 1.23%,
0.54%, and 0.69% for sepsis, pneumonia, bactere-
mia, and urinary tract infections, respectively [15].
The attributable risk of developing a nosocomial
bacterial infection from RBC transfusion was 0.5
per unit RBC, based on previous research delineat-
ing the increased risk of nosocomial infection asso-
ciated with RBC transfusion in critically ill patients
[15]. Therefore, the attributable risk of each speciﬁc
infection per course of therapy was calculated
according to the following equation: (baseline rate
of speciﬁc infection) ¥ 0.5 ¥ (number of RBC units).
RBC Transfusion Threshold
A  recent  study  showed  that  restricting  transfu-
sion administration to maintain Hct above approx-
imately 21% was safe and may reduce mortality
compared with administering transfusions to keep
Hct above approximately 30% [14]. This study
reduced the number of transfusions by 54% and the
number of patients receiving a transfusion by 33%.
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The transfusion thresholds used in the current cost-
effectiveness analyses were weighted mean Hcts of
approximately 27.3% and 25.7% for studies 1 and
2, respectively. To determine whether using an Hct
of 21% as the transfusion threshold alters the cost-
effectiveness of rHuEPO, we conducted a separate
sensitivity analysis, incorporating the lower trans-
fusion Hct threshold and the transfusion-sparing
results of the restrictive transfusion study.
Quality-Adjusted Life-years
QALYs were calculated independently for each
study  based  on  the  mean  age  and  sex  distribution
of the study population [38,39]. To derive baseline
QALYs for the respective ICU cohorts, the quality-
adjusted life expectancy (QALE) of the matching
age and sex population in the United States was
adjusted by the mortality rate and the annual utility
decrement corresponding to mixed ICU populations
[63–65]. For an ICU population, the cumulative
fatality rate at 12 months post hospital discharge
was 25% and the average EQ-5D tariff (utility) was
0.62 for subsequent years. For those who survived
12 months post hospital discharge (75%), we
assumed the life expectancy of a male and female to
be 80 and 83 years of age, respectively [63]. The
resulting discounted QALE (reported as QALYs)
were 10.56 QALYs for the cohort in study 1 [38]
and 15.16 QALYs for study 2 [39] (Table 1). In the
studies used to estimate utility decrement, approxi-
mately 55% of patients were male with a mean age
of 54 years [64,65]. Similar to the two rHuEPO
studies used in this analysis, the majority of primary
diagnoses of one study related to respiratory ill-
nesses [65] whereas the majority of primary diag-
noses of the other study related to trauma or
surgery [64]. The long-term utility impacts of ALI
or acute hemolytic reaction were assumed to be neg-
ligible and surviving patients were assumed to have
similar post ICU utilities as patients without these
reactions.
Early and late morbidities were considered with
all viral transmissions. Patients with HIV infection
were assumed to follow a disease progression of 4
phases based on previously published research:
patients in phase 1 are HIV infected, but there is no
impact  on  utility  for  9 years;  patients  in  phase
2 have an estimated utility of 0.76 for 4 years;
patients in phase 3 have an estimated utility of 0.65
for 1 years; and patients in phase 4 have an esti-
mated utility of 0.62 for 1 years before dying of
acquired immunodeﬁciency syndrome (AIDS) [66].
These estimates were applied to the age and sex-
adjusted life expectancy of ICU patients and
resulted in 7.52 QALYs for study 1 and 9.82
QALYs for study 2 for patients infected with HIV
due to RBC transfusions.
QALYs for patients infected with HB, HC and
HTLV-induced myelopathy were calculated using
previously published evidence of the impact on util-
ity and survival [47,67,68]. QALYs for HB, HC and
HTLV-induced myelopathy for studies 1 and 2 were
Table 1 Adverse effects of  RBC transfusions
RBC transfusion 
outcome
Incidence 
[3,6,15,55–62]
Cost 
estimate/event
[46–48, 56–62]
Quality-adjusted
life-years 
(study 1) 
[38,63–65]
Quality-adjusted
life-years  
(study 2)  
[39,63–65]
Acute lung injury 2 ¥ 10-4/RBC unit $6,180 10.56 15.16
Fatal 0.001/event
Acute hemolytic reaction 2.5 ¥ 10-6/RBC unit $1,779 10.56 15.16
Fatal 0.268/event
Febrile reaction 0.01/RBC unit  $169.53 10.56 15.16
Viral infections
HIV 2.75 ¥ 10-6/RBC unit $63,272 7.52 9.82
Hepatitis B 1.87 ¥ 10-5/RBC unit $12,209 9.12 13.09
Hepatitis C 2.0 ¥ 10-5/RBC unit $27,204 9.54 13.70
HTLV 2.25 ¥ 10-6/RBC unit 10.56 15.16
Myelopathy 0.04/event $14,632 10.10 14.70
Bacterial infections
Sepsis* 0.5/RBC unit $16,667 6.59 9.46
Fatal 0.376/event
Pneumonia* 0.5/RBC unit $12,375 7.39 10.61
Fatal 0.30/event
Bacteremia* 0.5/RBC unit $42,143 6.91 9.91
Fatal 0.346/event
Urinary tract* 0.5/RBC unit  $663 10.56 15.16
*Actual infection risk per course of  therapy calculated according to the following equation: (baseline rate of  speciﬁc infection) ¥ 0.5 ¥ (number of  RBC units) [15].
HIV, human immunodeﬁciency virus; HTLV, human T-cell lymphotrophic virus; RBC, red blood cell.
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9.12 and 13.09 QALYs; 9.54 and 13.70 QALYs;
and 10.10 and 14.70 QALYs, respectively. Because
of the acute nature of nosocomial bacterial infec-
tions, the utility impact was assumed to be negligi-
ble and surviving patients were assumed to have
similar post ICU utilities as patients without bacte-
rial infections. Therefore, decrements in QALYs for
bacterial infections were based solely on decreased
survival. QALYs for sepsis, pneumonia, and bacter-
emia for studies 1 and 2 were 6.59 and 9.46
QALYs; 7.39 and 10.61 QALYs; and 6.91 and 9.91
QALYs, respectively. It was assumed that survival
and utility were not inﬂuenced by the development
of urinary tract infections or rHuEPO-induced
adverse effects (DVT and thrombocytopenia).
Sensitivity Analyses
Univariate sensitivity analyses were conducted by
varying each input parameter by ±15% from the
base case value to identify the individual variables
with the greatest impact on the model results. Com-
prehensive threshold analyses were conducted for
parameters identiﬁed as having the greatest impact
on model results.
To more comprehensively examine the inherent
uncertainty in the assumptions underpinning the
model, a probabilistic sensitivity analysis using a
second-order Monte Carlo simulation was con-
ducted [69]. Incidence, cost, utility and effectiveness
parameters were assigned a probability distribution
incorporating the estimates from both studies and
reﬂecting the feasible range of values that each input
parameter could realize. The simulation then drew
one value from each distribution simultaneously
and calculated cost and effectiveness pairs. This
process was repeated 10,000 times to provide a
range of possible values given the speciﬁed proba-
bility distributions. Probabilities, incidence rates,
and utilities were assumed to follow a beta distri-
bution because they are normally distributed but
restricted to take on values between zero and one.
Estimates of mean cost were assumed to follow
either a gamma distribution or, when large enough
to ensure positive values, a normal distribution,
although individual estimates of cost are typically
not normally distributed, estimates of mean cost are
normally distributed [69].
Results
Cost-Effectiveness Estimates
For the base case analysis of studies 1 and 2, the
incremental costs of using rHuEPO to prevent RBC
transfusions were $1918 and $1439 and incremen-
tal effectiveness values were 0.0563 QALYs and
0.0305 QALYs, respectively (Table 2). The resulting
cost-effectiveness ratios were $34,088 and $47,149
per QALY for studies 1 and 2, respectively. The
incremental costs per allogeneic RBC unit avoided
were $827 and $11,072, respectively. Incorporating
the restrictive transfusion study into the model
resulted in an incremental cost of $2086 and an
incremental effectiveness of 0.0143 QALYs for a
cost-effectiveness ratio of $145,455 per QALY.
Sensitivity Analyses
The results of the univariate sensitivity analyses
revealed  that  the  attributable  risk  of  developing
a nosocomial bacterial infection per RBC unit
(assumed baseline rate of 0.5) was the most impor-
tant driver of incremental cost-effectiveness for
both studies. Threshold analysis demonstrated that
using rHuEPO was cost-effective for a willingness
to pay of $50,000 per QALY if the attributable risk
of nosocomial infection per unit of RBC is >0.36
and >0.46 in study 1 (Fig. 2) and study 2 (Fig. 3),
respectively. Univariate alteration of all other
parameters had little impact on the results of the
model. Even if the occurrence rates of viral infec-
tions are assumed to be nonexistent, as would be
the case if viral blood screening was ﬂawless, the
cost-effectiveness ratio does not exceed $47,246 per
QALY. For both studies, rHuEPO is cost-effective
only if RBC transfusions are associated with noso-
comial bacterial infections even if the price per unit
of rHuEPO is reduced by 100% (in addition to the
Table 2 Cost-effectiveness of  base cases
No rHuEPO
(study 1)
rHuEPO
(study 1)
No rHuEPO
(study 2)
rHuEPO  
(study 2)
Cost ($) 1928 3,846 1,595 3,034
Incremental cost ($) 1,918 1,439
Effectiveness (QALY) 10.4365 10.4928 15.0035 15.0340
Incremental effectiveness (QALY) 0.0563 0.0305
Incremental cost-effectiveness ratio ($/QALY) 34,088 47,149
QALY, quality-adjusted life-year.
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price per unit, there are costs associated with
administering rHuEPO—Fig. 4). This result is due
primarily to the fact that, absent an increased risk of
nosocomial infection due to RBC transfusion, the
incremental effectiveness of rHuEPO is negligible.
Varying the cost per unit of rHuEPO changes the
threshold at which the attributable risk of bacterial
infection is cost-effective (Fig. 4).
The 95% range of all input variables gives the
credible interval of values from the 2.5th and 97.5th
percentiles of the 10,000 second-order Monte Carlo
simulations (Table 3). Incremental cost varied from
$130 to $3594 and incremental effectiveness ranged
from -0.0099 to 0.1638 QALYs. The cost-
effectiveness of each of the 10,000 cost and effec-
tiveness pairs depends on its location relative to the
willingness to pay line. Overall, rHuEPO was cost-
effective in 52.0% of the Monte Carlo simulations.
If $100,000 per QALY is used as the willingness to
pay threshold, rHuEPO is cost-effective in 72% of
the simulations (Fig. 5). Given the speciﬁcations of
the distributions of the input parameters in the
model, these percentages may be interpreted more
generally as the probability that rHuEPO is cost-
effective at the respective willingness to pay thresh-
olds [70].
Figure 2 Threshold sensitivity analysis of  model 1 (study 1): impact
of  varying attributable risk of  nosocomial infection per RBC unit on
incremental cost-effectiveness ($/QALY). Assumed baseline rate is
0.5 and the threshold analysis demonstrated rHuEPO was cost-effec-
tive for a willingness to pay of  $50,000 per QALY if  the attributable risk
of  nosocomial infection per unit of  RBC is >0.36. rHuEPO, recom-
binant human erythropoietin; RBC, red blood cell.
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Figure 3 Threshold sensitivity analysis of  model 2 (study 2): impact
of  varying attributable risk of  nosocomial infection per RBC unit on
incremental cost-effectiveness ($/QALY). Assumed baseline rate is
0.5 and the threshold analysis demonstrated rHuEPO was cost-
effective for a willingness to pay of  $50,000 per QALY if  the attribut-
able risk of  nosocomial infection per unit of  RBC is >0.46. rHuEPO,
recombinant human erythropoietin; RBC, red blood cell.
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Figure 4 Bivariate sensitivity analysis varying the attributable risk of
nosocomial bacterial infections per unit of  RBC and the cost ($) per
unit of  rHuEPO by ±100%. The dashed lines represent the base case
assumptions ($0.0119/rHuEPO unit and risk of  infection of  0.50).
Points above the diagonal line are cost-effective for a willingness to pay
of  $50,000 per QALY. RBC, red blood cell; rHuEPO, recombinant
human erythropoietin.
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Discussion
Recombinant human erythropoietin therapy has
been shown to reduce the need for RBC transfu-
sions in ICU patients, but studies have not exam-
ined its cost-effectiveness in this patient population.
In the current study, decision analysis was used to
create economic models of the patient populations
involved in two previously published multicenter
clinical trials that were designed to assess rHuEPO
for reducing the need of RBC transfusions in adult
ICU populations. The results of both models sug-
gest that rHuEPO is cost-effective when used to
reduce RBC transfusion requirements in an ICU
population due largely to the reduction in the risk of
developing nosocomial bacterial infections associ-
ated with RBC transfusions. Although there is no
consensus about the acceptable upper limit of soci-
ety’s willingness to pay for a given intervention, the
range  of  base  case  estimates  from  both  models
is below the typical threshold of consideration
($50,000 per QALY). Using Monte Carlo analysis,
52.0% of simulations were deemed cost-effective if
$50,000  per  QALY  is  the  acceptable  upper  limit
of willingness to pay (Fig. 5). Of note, our results
differ from other analyses that have not shown
rHuEPO to be cost-effective in patient populations
outside the ICU [46–48]. Nevertheless, only our
analyses included the risk of bacterial infections
associated with RBC transfusions, an phenomenon
that currently is only recognized in ICU and cancer
populations [15–28].
Our estimates are generated from the results of
previously published clinical trials. Although mod-
eling two multicenter studies involving separate
ICU populations provides greater generalizability,
the results of the base case analyses are limited by
the patient populations and clinical criteria in these
studies. In general, the magnitude of effect is usually
smaller in practice than in controlled studies
because of poor patient selection, failure to properly
administer therapy, and inappropriate provisions of
other aspects of care [71]. Altering the use of
rHuEPO based on different criteria and/or patient
populations may alter the cost-effectiveness results.
Both studies initiated rHuEPO when Hct dropped
below 38%. It is difﬁcult to predict patients at risk
for developing anemia in the ICU and little infor-
mation exists to distinguish speciﬁc ICU popula-
tions at greatest risk. Altering the threshold for
initiating rHuEPO therapy may change the cost-
effectiveness results positively or negatively depend-
ing on whether the resultant effect is drug sparing or
transfusion requiring, respectively. Reducing the
Table 3 The 95% credible intervals of  input variables and
outcomes from Monte Carlo simulations
Input variables and outcomes Range*
Cost parameters ($)
rHuEPO (per unit)† 0.0057–0.0205
RBC (per unit)† 143–510
DVT (per rHuEPO course of  therapy)† 2630–6555
Thrombocytopenia (per rHuEPO 
course of  therapy)‡
1698–4074
Acute lung injury‡ 4238–8106
Acute hemolytic reaction‡ 1100–2451
Febrile reaction2 111–228
HIV‡ 44,242–82,542
Hepatitis B‡ 10,217–14,146
Hepatitis C‡ 21,389–33,084
HTLV-induced myelopathy‡ 9700–19,491
Sepsis‡ 11,728–21,591
Pneumonia‡ 9426–15,276
Bacteremia‡ 34,429–51,993
Urinary tract infection‡ 503–819
Dosage and incidence parameters
rHuEPO (total units)† 81,634–232,178
RBC rHuEPO (total units)† 3.84–5.70
RBC no rHuEPO (total units)† 3.86–8.45
Probability of  RBC rHuEPO§ 0.377–0.580
Probability of  RBC no rHuEPO§ 0.493–0.659
DVT (per rHuEPO course of  therapy)§ 0.015–0.051
Thrombocytopenia (per rHuEPO 
course of  therapy)§
0.062–0.090
Acute lung injury (per RBC unit 
transfused)3
9.71 ¥ 10-5-3.45 ¥ 10-4
Fatality rate§ 5.79 ¥ 10-4-2.06 ¥ 10-3
Acute hemolytic reaction (per RBC unit 
transfused)§
1.21 ¥ 10-6-4.27 ¥ 10-6
Fatality rate§ 0.225–0.314
Febrile reaction (per RBC unit 
transfused)§
4.76 ¥ 10-3-1.69 ¥ 10-2
Hepatitis B (per RBC unit transfused)§ 9.04 ¥ 10-6-3.19 ¥ 10-5
Hepatitis C (per RBC unit transfused)§ 9.62 ¥ 10-6-3.41 ¥ 10-5
HIV (per RBC unit transfused)§ 1.32 ¥ 10-6-4.69 ¥ 10-6
HTLV (per RBC unit transfused)§ 1.10 ¥ 10-6-3.85 ¥ 10-6
Myelopathy rate§ 1.96 ¥ 10-2-6.76 ¥ 10-2
Attributable risk of  infection (per RBC 
unit transfused)†
0.138–1.089
Sepsis (baseline)§ 1.22 ¥ 10-3-1.80 ¥ 10-3
Fatality rate§ 0.319–0.435
Pneumonia (baseline)§ 1.00 ¥ 10-2-1.48 ¥ 10-2
Fatality rate§ 0.252–0.349
Bacteremia (baseline)§ 4.39 ¥ 10-3-6.52 ¥ 10-3
Fatality rate§ 0.293–0.402
Urinary tract infection§ 5.61 ¥ 10-3-8.30 ¥ 10-3
QALYs
ICU1 (QALE) 8.25–18.38
Hepatitis B decrement† 1.15–2.50
Hepatitis C decrement† 0.81–1.78
HIV decrement† 2.58–8.98
HTLV-induced myelopathy decrement† 0.37–0.56
Cost-effectiveness results
Total expected cost rHuEPO ($) 2119–5349
Total expected cost no rHuEPO ($) 798–3236
Expected effectiveness rHuEPO (QALY) 8.20–18.28
Expected effectiveness no rHuEPO 
(QALY)
8.17–18.19
*The 95% intervals give the credible range of  values from the 2.5th and 97.5th
percentiles of  the 10,000 second-order Monte Carlo simulations.
†Gamma distribution.
‡Normal distribution.
§Beta distribution.
DVT, deep venous thrombosis; HIV, human immunodeﬁciency virus; HTLV,
human T-cell lymphotrophic virus; QALY, quality-adjusted life-year; RBC, red
blood cell; rHuEPO, recombinant human erythropoietin.
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transfusion thresholds from weighted mean Hct val-
ues of approximately 27.3% and 25.7% used in
Studies 1 and 2, respectively, to the 21% threshold
shown to be safe in the restrictive transfusion study
produced a less favorable cost-effectiveness ratio of
$145,455 per QALY [14]. The beneﬁt of lowering
the Hct transfusion threshold to 21% is likely over-
estimated because the comparative arm in the
restrictive transfusion study administered transfu-
sions to maintain Hct above approximately 30%.
Of note, surveys and cohort studies conducted after
the publication of the restrictive transfusion study
indicate that the majority of ICU practitioners
continue to  transfuse  RBC  units  to  maintain  Hct
at approximately 24% to 27% [3,4,72,73]. Future
comparative studies of rHuEPO, however, should
incorporate a restrictive transfusion protocol to
determine the effectiveness of rHuEPO against
evidence-based practice.
We found the attributable risk of developing
nosocomial bacterial infections to be the most
important determinant of cost-effectiveness. Several
studies have demonstrated an association between
RBC transfusions and infection risk but the degree
of risk is variable and related to the cumulative
number of RBC units transfused [3,15–28]. We
used an attributable risk of 0.5 per RBC unit based
on previously published evidence, but the thresh-
olds of risk to maintain cost-effectiveness are 0.36
and 0.46 for a willingness to pay of $50,000 per
QALY or less for studies 1 and 2, respectively. These
thresholds are within the range of uncertainty
reported in the literature. In addition, altering the
cost per unit of rHuEPO substantially impacts the
threshold of bacterial infection risk that is cost-
effective (Fig. 4). Immunomodulation is the most
likely explanation for enhanced infection risk with
RBC transfusions because they have been shown to
downregulate macrophage class II antigen produc-
tion, decrease B-cell stimulation and CD4 helper T-
cell number, and impair natural killer cell activity
[74,75]. The immunosuppressive effect is related to
leukocyte exposure with subsequent sensitization
[3]. Some countries have implemented universal leu-
codepletion of RBC transfusions but the estimated
cost to do so in the United States exceeds $500 mil-
lion [3]. We did not assume universal leucodeple-
tion because it is unclear whether this practice alters
outcomes of critically ill patients [49,50]. If proven
effective, leucodepletion would be a competing
strategy for reducing bacterial infections and would
minimize the beneﬁt associated with rHuEPO.
The results of both studies included in the
analyses showed that approximately 10% fewer
patients require RBC transfusions with rHuEPO
therapy  [38,39].  Nevertheless,  the  mean  number
of transfusions per patient varied substantially
between studies. Study 1 saved 2.32 RBC units per
patient requiring a transfusion, whereas study 2
saved only 0.13 RBC units. This difference between
studies is likely due to dosage regimen variations
because study 1 used aggressive early rHuEPO ther-
apy for a mean cumulative dose of 190,900 units
and study 2 used weekly administration for a mean
cumulative dose of 102,400 units. Based on the
results of the sensitivity analyses, however, both
dosing strategies appear cost-effective. Whether
alternative rHuEPO dosage regimens are cost-effec-
tive is unknown. We used average wholesale price
discounted 15% to represent rHuEPO acquisition
cost [45]. This may not accurately reﬂect the speciﬁc
contract price of certain institutions, but is indica-
tive of the average contract price in the United
States and allows for more general application of
the results.
We included the costs of thrombocytopenia and
DVT associated with rHuEPO therapy. Study 1
showed a substantial, although statistically insignif-
icant, increase in the occurrence of thrombocytope-
nia with rHuEPO. Study 2 did not report
thrombocytopenia as an independent adverse effect.
DVT is a recognized rare event associated with
rHuEPO therapy. The exclusion of these side effects
had no impact on the model results.
The incidences and costs of adverse effects
associated with RBC transfusions were obtained
from published sources examining the use of RBC
transfusions  in  critically  ill  patients  or  rHuEPO
for reducing transfusions in other populations
[3,6,15,46–48,55–65]. Neither the incidence rates
nor the costs associated with the adverse effects of
RBC transfusion had a signiﬁcant impact on the
results of the model because of the fact that these
events  are  extremely  rare.  Of  note,  we  included
only adverse effects that were well established and
assumed similar adverse effect proﬁles for each unit
of RBC. Other possible complications not included
in the current analysis are psychrophile-induced
shock, blood stasis, post-transfusion purpura,
suppression of erythropoiesis, and alterations of
oxygen carrying capacity with RBC storage [6].
Including these effects, however, would enhance the
cost-effectiveness of rHuEPO.
Estimating the baseline QALE of an average ICU
population is inherently unwieldy because of the
heterogeneous nature of any ICU. QALE varies
according to patient demographics, the reason for
ICU admission, and associated patient utility esti-
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mates. Nevertheless, the same baseline QALE esti-
mate was applied to both groups of a study and thus
any bias in the baseline QALE estimate would
equally impact both groups. We made assumptions
that several adverse effects associated with transfu-
sions would not affect post ICU patient utility (e.g.,
ALI, acute hemolytic reactions, bacterial infec-
tions). These events most likely do impact QALYs
but limited data exist describing long-term decre-
ments. Including these effects, however, would
enhance the cost-effectiveness of rHuEPO.
Beyond reducing RBC transfusions, studies have
not shown other clinical beneﬁts with rHuEPO
therapy in critically ill patients [36,37,40,41]. In
study 2, there was a trend toward reduced ICU
readmission rate with rHuEPO therapy (9.8% vs.
13.3%, P = 0.07, respectively) [39]. Any additional
clinical beneﬁt would enhance the cost-effectiveness
associated with rHuEPO use.
The estimates used in modeling the cost-
effectiveness of rHuEPO are based on multiple
sources and assumptions and are therefore subject
to uncertainty. Hence, we urge some degree of
caution when interpreting these results. Moreover,
cost-effectiveness analyses serve as one piece of
information in the decision-making process when
considering the implementation of health interven-
tions. Nevertheless, we have attempted to examine
the impact of this inherent uncertainty on the results
of the model through the use of comprehensive sen-
sitivity analyses. All estimates and assumptions
were simultaneously varied to include all plausible
values. After incorporating these extreme values,
the use of rHuEPO to reduce transfusion require-
ments in an ICU population was cost-effective in
52.0% of the simulations.
Conclusions
The results of these models suggest that using
rHuEPO to reduce RBC transfusions in an ICU
population is cost-effective, due primarily to the
risk of nosocomial bacterial infection associated
with RBC transfusions. Our ﬁndings were robust to
a wide range of sensitivity analyses and two sepa-
rate cost-effectiveness models. Future studies should
focus on clinical outcomes other than RBC transfu-
sion independence, determination of patients most
at risk for developing anemia in the ICU, rHuEPO
use while incorporating a restrictive transfusion
protocol, and a priori cost-effectiveness analysis.
Source of ﬁnancial support: No ﬁnancial support for this
project. The authors have no ﬁnancial interest in the mak-
ers of erythropoietin  and are not being paid as consult-
ants for work related to erythropoietin. Preliminary
results presented as a poster at the International Society
for Pharmacoeconomic and Outcomes Research Eighth
Annual International Meeting in May 2003 in Arlington,
VA.
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